Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Company Deals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Fineline Cube Mar 4, 2026
Company Deals

Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III

Fineline Cube Mar 4, 2026
Company Deals Drug

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Fineline Cube Mar 4, 2026
Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Fineline Cube Mar 4, 2026
Company Deals

Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation

Fineline Cube Dec 27, 2023

Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou...

Company Deals

XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology

Fineline Cube Dec 27, 2023

XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly...

Company Drug

Taiwan FDA Reviews Nefecon New Drug Application from Everest Medicines

Fineline Cube Dec 27, 2023

China-based Everest Medicines (HKG: 1952) has announced that the New Drug Application (NDA) for Nefecon...

Company Deals

J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences

Fineline Cube Dec 27, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...

Company Deals

BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition

Fineline Cube Dec 27, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...

Company Drug

Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study

Fineline Cube Dec 27, 2023

The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...

Policy / Regulatory

China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP

Fineline Cube Dec 27, 2023

The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...

Company Medical Device

Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch

Fineline Cube Dec 27, 2023

Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...

Policy / Regulatory

China Charts Course for Advanced Disease Prevention and Control System by 2030

Fineline Cube Dec 27, 2023

China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...

Company Deals

Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug

Fineline Cube Dec 27, 2023

China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Company Drug

Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study

Fineline Cube Dec 27, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Deals

Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million

Fineline Cube Dec 27, 2023

Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...

Company Drug

Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109

Fineline Cube Dec 27, 2023

Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...

Company Deals

Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment

Fineline Cube Dec 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...

Company Deals

Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio

Fineline Cube Dec 27, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...

Company Deals

AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal

Fineline Cube Dec 26, 2023

Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...

Policy / Regulatory

China’s NHC Releases Third List of Recommended Generic Drugs for Development

Fineline Cube Dec 26, 2023

The National Health Commission (NHC) of China has released its third list of drugs recommended...

Company Drug

FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted under priority review a filing from...

Company Deals Drug

AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial

Fineline Cube Dec 26, 2023

AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...

Posts pagination

1 … 388 389 390 … 630

Recent updates

  • Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label
  • Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development
  • Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter
  • Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market
  • Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.